SRDX (Surmodics) Valuation Rank


SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
GF Value $32.10
! 5 Warning Signs
View Full Analysis

What is Surmodics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Surmodics Valuation Rank Related Terms

SRDX
51GF Score
Surmodics Inc SRDX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

  • Valuation Rank:
  • GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price
$32.10
GF Value